Roquette announce a strategic investment with Beren Therapeutics P.B.C. and the beginning of an innovation agreement to maximise the potential of Beren'scyclodextrin technologies and their medical applications.

Roquette is a provider of pharmaceutical excipients and a world leader in plant-based ingredients.

The primary goal of Beren, a vertically integrated biopharmaceutical business, is to address the biggest health concerns in the world. Roquette is aware of Beren'sresearchs transformative potential to change the market and the lives of millions of people around the world.

Jason Camm, CEO of Beren Therapeutics, P.B.C.said, “Working with Roquette is a natural fit. Bringing our teams closer together can only lead to faster innovation and opportunities that wouldn’t exist if we weren’t looking to engage outside our traditional domains.” He further added, “Both our missions align around pushing the boundaries of scientific innovation to benefit humanity, particularly when it comes to efficient and sustainable manufacturing processes.”

“Teaming up with Roquette is another step forward in our efforts to work across our ecosystem to accelerate ‘access for all,’” said Frank Langston, Beren’s Senior Vice President of Business Strategy. He further added, “We’re showcasing how outside-the-box collaboration can lead to greater societal impact and allow us to rapidly explore the untapped potential of our technology beyond our core business.”